Comparison of the Effect of Ranibizumab and Aflibercept on Changes in Macular Choroidal Thickness in Patients Treated for Diabetic Macular Edema

Table 2

Choroidal thickness (CT) and change between M0 and M5 expressed in microns in the different locations of the 3000 μm macular choroidal mapping outside the central 1000 μm in the aflibercept, ranibizumab, and control groups.

	M0	M5	Change
Aflibercept
CT sup	204.5	190.5	−14	0.008
CT temp	200.5	184.1	−16.4	0.003
CT inf	182.9	169. 8	−13.1	0.03
CT nasal	190.8	172.9	−17.9	0.002
Ranibizumab
CT sup	270.5	264.7	−5.8	0.19
CT temp	254.2	248.7	−5.5	0.14
CT inf	268.2	254.6	−13.6	0.17
CT nasal	252.2	247.6	−4.6	0.16
Control
CT sup	240.4	244.3	+3.9	0.86
CT temp	233.5	226.6	−6.8	0.29
CT inf	232	224.9	−7.1	0.13
CT nasal	232.5	232.6	+0.1	0.99

CT sup, superior quadrants; CT temp, temporal quadrants; CT inf, inferior quadrants; CT nasal, nasal quadrants. represents the statistical significance, and the significant values are in bold.